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Abstract
Alongside Pdx1 and Beta2/NeuroD, the transcription factor MafA has been shown to be instrumental in the maintenance of
the beta cell phenotype. Indeed, a combination of MafA, Pdx1 and Ngn3 (an upstream regulator of Beta2/NeuroD) was
recently reported to lead to the effective reprogramming of acinar cells into insulin-producing beta cells. These experiments
set the stage for the development of new strategies to address the impairment of glycemic control in diabetic patients.
However, the clinical applicability of reprogramming in this context is deemed to be poor due to the need to use viral
vehicles for the delivery of the above factors. Here we describe a recombinant transducible version of the MafA protein
(TAT-MafA) that penetrates across cell membranes with an efficiency of 100% and binds to the insulin promoter in vitro.
When injected in utero into living mouse embryos, TAT-MafA significantly up-regulates target genes and induces enhanced
insulin production as well as cytoarchitectural changes consistent with faster islet maturation. As the latest addition to our
armamentarium of transducible proteins (which already includes Pdx1 and Ngn3), the purification and characterization of a
functional TAT-MafA protein opens the door to prospective therapeutic uses that circumvent the use of viral delivery. To our
knowledge, this is also the first report on the use of protein transduction in utero.
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Introduction
Maf proteins belong to a large class of transcription factors
originally described as viral oncogenes [1]. They are characterized
by the presence of a basic leucine zipper (b-Zip) domain and the
ability to bind to DNA MARE (Maf Recognition Elements) either
as homodimers or heterodimers with other b-Zip proteins. These
transcription factors have been associated with the regulation of
multiple differentiation processes, including hematopoiesis, skin
and lens development and hind-brain segmentation [2,3]. The
best characterized Maf factors expressed in the pancreas are MafA
and MafB [4]. Their role in pancreatic development has been
difficult to ascertain, especially because their knockout has no
overt effects in the specification of the major lineages of the organ
[5,6]. However, MafA 2/2 mice display glucose intolerance and
develop age-dependent diabetes [5], and MafB knockouts exhibit
some defects on endocrine cell maturation [6]. Since all Maf
factors compete for the same MARE sites, their temporal and
spatial pattern of expression is likely to affect developmental
outcomes. Although MafB has also been recently shown to be
essential for the appropriate regulation of Pdx1, Nkx6.1 and
GLUT-2 in the final stages of islet b cell maturation [7], recent
evidence suggests that a switch from MafB to MafA might be
critical for the embryonic maturation and prolonged survival/
function of b cells [4].
MafA has been found to selectively bind to the C1 (human)/
RIPE3b (rat) element of the insulin gene promoter of b cells [8].
This sequence is of fundamental importance in the regulation of
glucose-dependent insulin secretion [9]. While MafA is not a
strong transactivator of the insulin promoter by itself, a synergistic
action with Pdx1 and NeuroD/Beta2 has been demonstrated [10].
These two other factors are not exclusive of b cells, but this
particular combination (Pdx1, NeuroD/Beta2 and MafA) is.
Therefore, it has been hypothesized that the b cell-restricted
expression of insulin is dictated by the concerted action of these
three factors [11]. Perhaps not surprisingly, their ectopic
expression in hepatocytes (which are ontogenically and physiolog-
ically related to b cells [12]) resulted in the activation of insulin
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(Pdx1, MafA and Ngn3, an upstream regulator of NeuroD/Beta2
[14]) also resulted in the in vivo reprogramming of pancreatic
exocrine cells into b cells [15].
In addition to the regulation of insulin secretion, MafA may also
be involved in other b cell processes by directly regulating genes
such as prohormone convertase 1/3 (PC1/3), the glucagon-like
peptide 1 receptor (GLP1-R), the glucose transporter GLUT-2,
glucokinase, pyruvate carboxylase and the subunits Kir6.2 and
SUR1 of potassium channels, as well as the transcription factors
Nkx6.1, NeuroD/Beta2 and Pdx1 [16].
From a translational point of view, the emerging role of this
gene as a potential therapeutic target for diabetes has not gone
unnoticed. MafA is now acknowledged as a key element in most
reprogramming strategies for islet b cell neogenesis [15,17,18].
However, as the use of viral vehicles to deliver reprogramming
factors is considered unsafe in the context clinical therapies
[19,20], the quest for non-viral alternatives is a timely one. One
such alternative is protein transduction, a technology by which
membrane-permeable domains (protein transduction domains, or
PTDs) enable recombinant proteins to efficiently penetrate into
cells. One of the best studied PTDs is the 11-aa peptide derived
from the basic domain of the TAT/HIV transactivator protein
[21]. TAT is bound by charged heparan sulfate chains of cell
membrane proteoglycans, taken up by macropinocytosis and then
released to the cytoplasm [22,23]. Due to its ease of engineering
and effectiveness, TAT and other synthetic cationic relatives [24]
have been used extensively to deliver full-length functional
proteins both in vitro and in vivo [21]. Our team has been among
the pioneers of protein transduction for pancreatic islet applica-
tions [25,26,27,28,29,30,31,32,33]. We have also previously
described the generation of TAT-Ngn3, a transducible version
of the pro-endocrine transcription factor that choreographs
pancreatic endocrine cell specification. The use of this protein
on pancreatic progenitor cells in vitro resulted in the targeted
stimulation of a and b cell differentiation according to the
developmental stage of the cells [34]. Here we report the
purification and use of recombinant TAT-MafA in a variety of
biological systems, including live developing mouse embryos onto
which the protein was injected intracardially by ultrasound
guidance techniques developed by our team (Nieto and Pastori,
unpublished results). The functionality of the protein in the
experimental group was evidenced by a significant increase of
MafA target genes (chiefly insulin), as well as by changes in islet
cytoarchitecture at birth. These findings are discussed in the
context of the potential use of TAT-MafA not only as an
important tool for developmental studies, but also as a valuable
addition to our reprogramming armamentarium for therapeutic
purposes.
Results
TAT-MafA effectively transduces living cells in vitro
In order to test whether TAT confers MafA the ability to
penetrate across cellular membranes, mouse pancreatic insulino-
ma cells MIN-6 and b-TC3 were incubated with Alexa Fluor 568-
labeled protein (final concentration in culture medium: 1 mM).
Hoechst was used as a nuclear counter-staining in living cells.
Figure 1a shows a time course experiment (2–24 h) using the latter
cell line. In agreement with our previous experience with other
TAT-fused proteins, virtually 100% of the cells were transduced as
early as 2 h after addition of the labeled protein to the medium.
Most of the TAT-MafA staining remains in cytoplasmic macro-
pinocytotic vesicles at 24 h [23], but nuclear co-localization of
released TAT-MafA was also demonstrated by confocal micros-
copy (figure 1b). This was particularly evident at later time points.
MIN-6 cells displayed similar uptake kinetics, although in this cell
line overt transduction could not be seen until 4 h of incubation
(data not shown). The stability of the protein over longer
Figure 1. TAT-MafA uptake in b-TC3 cells. (A)TAT-MafA protein
(1 mg/ml) was labeled with Alexa Fluor 568 and added to the culture
medium of b-TC3 cells grown in glass bottom dishes (P35G-1.5-20-C
35 mm, MatTek Corporation, Ashland, MA) to ensure maximal optical
clarity for live confocal microscopy. Hoescht (blue) was used as nuclear
counter-staining (first column). An overlay of both channels is seen in
the last column. The culture medium was removed and cells washed in
PBS prior to each observation in order to eliminate free extracellular
immunofluorescence background. Disturbance of the cultures prior to
the time of observation was prevented by plating each individual group
(time point) independently. Size bar: 20 mm. (B) Detail of nuclear
localization of the protein after 8 h by live confocal microscopy
(staining as above). Size bar: 5 mm.
doi:10.1371/journal.pone.0022364.g001
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indicate that TAT-MafA can be efficiently transduced in vitro.
Recombinant TAT-MafA binds to the insulin promoter
TAT-MafA protein was purified as described in the Methods
section. Optimization of the process results in high yield (.1 mg)-
high purity (80–90%) protein. TAT-MafA can be detected as a
,50 kD band by automated gel electrophoresis using a Experion
bioanalyzer (Bio-Rad, Hercules, CA) (fig. 2a). The identity of the
band was confirmed by Western blot using a rabbit polyclonal
anti-MafA antibody (Abcam ab17976) (fig. 2b).
In order to determine whether TAT-MafA binds to its
appropriate DNA target within the Insulin promoter, an
electrophoretic mobility shift assay (EMSA) was done as indicated
above. The sequence ATGGTCCGGAAATTGCAGCCT-
CAGCCCCCAGCCATC (2139 to 2104 of the insulin promot-
er) was synthesized at Sigma-Aldrich (St. Louis, MO) for use in
hybridization studies. This sequence encompasses the C1 box of
the insulin promoter, a highly conserved region to which MafA is
known to bind in a selective manner [35]. As mutational analysis
has shown that the formation of MafA dimers capable of DNA
binding is phosphorylation-dependent [36,37], we used the ERK2
kinase (New England Biolabs, Ipswich, MA) to activate TAT-
MafA before the reaction. As shown in fig. 2c, the use of
phosphorylated TAT-MafA results in a significant mobility shift.
With the exception of unphosphorylated TAT-MafA (which in our
hands also exhibited basal DNA-binding activity), no other
controls induced any band displacement.
TAT-MafA has biological activity in vitro
A prediction of an effective binding to the insulin promoter in
vitro would be an increase in insulin expression in relevant cell
substrates. A set of experiments in which mouse insulinoma cells
(b-TC3) were cultured for 24 h with the protein showed that
purified TAT-MafA increased insulin expression by about 15-fold
(data not shown). However, recent transgenic experiments indicate
that ectopic expression of MafA too early during pancreatic
development arrests the differentiation and proliferation of
progenitor cells, possibly by inducing cyclin kinase inhibitors p27
and p57 [38]. A conclusion of these studies was that MafA may be
used to enhance maturation, rather than specification, of b cells
from their progenitors. We confirmed this observation by treating
explanted e14.5 pancreatic buds with TAT-MafA for 48 h. Real-
Time qRT-PCR analysis showed a significant down-regulation of
the key b cell markers insulin 1, insulin 2 and GLUT-2 compared
to vehicle-treated controls (fig. 2d). This down-regulation did not
entail any loss in overall viability. In conclusion, purified TAT-
MafA is able to recognize its biological DNA target and induce the
expression of the insulin promoter, but has a detrimental effect on
pancreatic progenitor cells at an early stage of development
(e14.5). These results indicate that TAT-MafA is active and
functions in a manner consistent with the predicted biological
activity of the native protein.
Targeting of the developing pancreas in utero by
injection of transducible proteins
We decided to test the hypothesis that TAT-MafA has an effect
on the maturation of late-stage pancreatic progenitors. However,
unlike e14.5 pancreatic buds, late-stage fetal pancreata are large
structures whose culture poses significant challenges in terms of
appropriate oxygen and nutrient diffusion. Also, despite the known
ability of TAT-fused proteins to go across relatively think
structures (such as isolated islets), in our experience their
penetration is rather limited beyond 300–400 microns in vitro.
Because of the above considerations, the observation that we could
not detect any significant difference at the gene expression level
between TAT-MafA-supplemented and control e17.5 cultured
pancreata was not surprising (Figure S1). However, the develop-
ment of a novel intrauterine injection technique afforded us the
possibility to study the role of TAT-MafA in a much more relevant
in vivo model. In essence, using an ultrasound-guided approach,
protein can be injected directly into the heart of embryos, from
where it is distributed to all tissues, including the pancreas. This
system offers a critical advantage over the in vitro setting, as the
effects of the treatment can be observed without disturbing the
native environment of the developing organ. Such advantage is
especially significant for the study of late-stage pancreatic
progenitors, because, as mentioned above, the large size of the
pancreas at this time makes it difficult to establish viable
Figure 2. In vitro activity of TAT-MafA. (A) Experion
TM virtual run
of the last the purest eluate of TAT-MafA (far right), preceded by the
three previous ones. (B) Western blot (MafA antibody) was used to
confirm the identity of the purified protein. (C) Electrophoretic Mobility
Shift Assay (EMSA). All samples include biotin-labeled DNA. 1. Labeled
DNA alone (baseline control); 2. TAT-MafA (no competitor); 3. TAT-
MafA+unlabeled DNA competitor (control); 4. Kinase treated TAT-MafA;
5. Kinase treated TAT-MafA+unlabeled DNA competitor (control); 6.
Kinase alone (control); 7. Kinase+unlabeled DNA competitor (control)
(D) qRT-PCR to measure relative expression of key pancreatic genes
(insulin 1, insulin 2 and Glut-2) in e14.5 buds treated with TAT-MafA or
vehicle. Black columns: control (vehicle); grey columns: TAT-MafA
treatment. Bars: standard error.
doi:10.1371/journal.pone.0022364.g002
TAT-MafA Accelerates Islet Maturation In Vivo
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22364organotypic cultures. This technology could also be potentially
used in the context of human pre-natal therapy for a variety of
conditions requiring in utero interventions (see Discussion).
We used a labeled TAT-fused version of b-galactosidase (TAT-
bgal) to establish the technique. Thus, Alexa Fluor 568-labeled
TAT-bgal was injected directly into the heart of e17.5 embryos as
described in Methods. Viability remains high and most embryos
go to term normally (data not shown). In these preliminary
experiments, the embryos were retrieved 4 h after the injection
and their pancreata examined by multi-photon confocal micros-
copy. Figure S2 shows that the pervasion of TAT-bgal throughout
the majority of the organ is quite evident. Next, we repeated these
experiments with our protein of interest (TAT-MafA), also labeled
in the same fashion. As shown in figure 3, TAT-MafA accumulates
effectively both in the liver and the pancreas, but very little in
other peripheral organs such as the brain, the kidney or the heart.
We therefore demonstrate that intra-cardial injection allows for
the relatively selective mobilization of the protein to the hepato-
pancreatic region.
Injection of TAT-MafA to developing embryos in vivo
induces changes in pancreatic development
In order to test the above hypothesis, we injected e17.5 embryos
with purified TAT-MafA and allowed them to go to term.
Controls were injected with the same vehicle used for the protein.
All the embryos retrieved from each mother (4 females/group, 7–8
embryos/female) were pooled and considered an individual n for
statistical analyses. This sample size (n=4) was determined to have
adequate power to detect statistical differences with an alpha error
level of 5% and beta error level of 50%. Upon birth, pups were
sacrificed and their pancreata collected for further analysis. No
significant differences could be observed either in the size or the
gross anatomy of the embryos from each group. The pancreata
were similar at the macroscopic level. Tissue samples were taken
for qRT-PCR, insulin extraction and immunofluorescence (IF). As
shown in figure 4a, the level of expression of all the pancreatic
markers analyzed by quantitative real-time RT-PCR was elevated
in the experimental group vs. the control. This increase was
statistically significant for the endocrine cell markers glucagon
(P=0.0254), insulin 1 (P=0.0043) and insulin 2 (P=0.0363). The
pancreatic content of insulin in the TAT-MafA-treated embryos
doubled that found in controls, as measured by ELISA (n=4;
P=0.0009) (figure 4b). IF analysis confirmed some of these
findings. Islets from TAT-MafA-treated embryos are rounded and
compact, with bright insulin and glucagon staining (figure 5b and
d). Control pancreata, in contrast, exhibit smaller, more ragged
and less organized islets, with weaker insulin and glucagon signal
(figure 5a and c). No differences in proliferation were noted (data
not shown). Immunostaining for prohormone convertase 1 (PC1/
3, encoded by the Pcsk1 gene), an enzyme critically involved in the
biosynthesis of insulin, appears to be similar in both groups despite
a trend towards higher gene expression levels in the experimental
group (figure 5c and d). However, staining for the glucose
transporter 2 (Glut-2) could be observed in TAT-MafA-treated
pancreata co-localizing with hormone-positive cells (figure 5f) but
it was virtually undetectable in the control group (figure 5e). This is
in agreement with the trends observed in the gene expression
analyses.
Discussion
We present here a novel combination of two techniques (protein
transduction and in utero intracardial delivery) with a great
potential both for the design of basic developmental research
and human therapy. We have effectively purified and demon-
strated the biological function of TAT-MafA, a transducible
version of a protein that in recent years has garnered significant
attention in the field of pancreatic development and reprogram-
ming.
The flexibility afforded by TAT-MafA for the design of basic
developmental studies is difficult to match by conventional
transgenic strategies. Even with the caveat that there is a potential
for off-target effects (although accumulation is largely hepato-
pancreatic, the protein will be delivered to virtually every tissue),
the route herein described opens new avenues of research that
may complement, and even occasionally replace, experimental
designs based on the generation of transgenic animals. Our
findings on the effect of MafA on the e17.5 developing pancreas,
for instance, would have otherwise required the cumbersome
generation of transgenic mice with an inducible promoter. Our
approach, in contrast, entailed only the ultrasound-guided intra-
cardial injection of TAT-MafA at the desired developmental stage.
Of note, as we have been able to inject embryos as small as e10.5
without significant loss of viability (Nieto et al, Nieto and Pastori,
unpublished results), the applicability range of this technique spans
organogenesis almost in its entirety.
Our observations clearly set the stage for more in-depth studies
about the biological role of TAT-MafA in b cell specification. An
obvious development of the present work, for instance, would be to
examine functional parameters of islets from TAT-MafA-treated
animals. However, since our primary objective was to demonstrate
that TAT-MafA would work as predicted in the context of a novel
delivery approach, such experiments were deemed to be beyond
the scope of this study. Having said this, our findings are not only
consistent with what is known about the function of the native
gene, but also unveil some potential new functions that warrant
additional study. Particularly intriguing is the observation that
MafA may be associated with the process of islet coalescence and
cytoarchitecture reshaping. It is known that neonatal islets
typically exhibit a disorganized morphology, with less defined
contours than those of adult origin [39]. While our controls adhere
to that pattern, TAT-MafA injected embryos have larger, rounder
and more adult-like islets. The molecular mechanism behind this
phenomenon remains unclear, but it has been proposed that the
acquisition of glucose-responsive insulin secretion requires an
extensive remodeling of the islet cytoarchitecture affecting crucial
regulatory events such as paracrine and cell-to-cell interactions
[39]. At the molecular level, it has been shown that the maturation
of b cells is accompanied by up-regulation of the expression of
tight and adherens junction-associated proteins in islet cells [40],
with quantifiable changes in the pattern of connexins, gap junction
membrane density and coupling changes [41]. In this context, a
simple explanation for our results would be that MafA would
contribute to a faster islet remodeling just by accelerating b cell
maturation, which is in fact its best-known function [4,38]. Our
own observation that functional b cell genes such as PC1/3, Glut-
2 or GK are up-regulated upon TAT-MafA treatment would
support this conclusion.
In addition to its well-documented role in the maturation of b
cells, MafA has achieved –somewhat unexpectedly– notoriety as a
key component of a triad of transcription factors that also include
the better-known master regulators Pdx1 and Ngn3. The joint
ectopic expression of these three factors in pancreatic acinar tissue
results in their permanent reprogramming to insulin-producing b
cells that could be used for the treatment of type 1 diabetes [15].
Although the clinical implications of such biotechnological feat
were dampened by the need to use adenoviral vehicles, our
findings timely complement the already reported generation of
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This opens the door to the controlled in vitro reprogramming of
pancreatic exocrine tissue by means of protein transduction, a
technique that completely circumvents the safety concerns posed
by the use of viruses. The amount of tissue that is now routinely
discarded after each clinical islet isolation (80–90% of which is
arguably exocrine) would represent an invaluable potential source
of insulin-producing cells. The sheer numbers of cells that could be
cultured from such discards would make expansion almost
unnecessary.
Our work also presents another significant innovation for the
conduct of developmental biology studies, namely the in vivo
intracardial injection of an agent suspected of having an effect on
fetal ontogeny. Although there are previous reports describing in
utero and fetal intracardial injection [43,44], this is the first report
on the use of bioactive transducible proteins. From a therapeutic
Figure 3. In vivo penetrability of TAT-fused proteins after in utero intra-cardiac injection. Examined organs are indicated. A, B and C
represent Alexa Fluor 568-labeled TAT-bMafA (red), phase contrast of tissue, and composite image, respectively. Images were obtained 4 h after the
injection by two-photon confocal microscopy. Size bar: 500 mm.
doi:10.1371/journal.pone.0022364.g003
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may also present distinct advantages over umbilical cord injection
(typically hindered by poor placental transfer [45]) for a variety of
potentially life-threatening prenatal conditions such as fetal
cardiac arrhythmia [45], congenital adrenal hyperplasia [46] or
fetal hemolytic disease [47,48].
Materials and Methods
Protein subcloning and purification
The gene sequence of human MafA was optimized for
expression in E. coli by Genscript (Piscataway, NJ) and then
cloned into the multicloning site of pTAT-2.1 (pET28) expression
Figure 4. Gene and protein expression analysis of TAT-MafA-treated pancreata in neonate pups. (A) qRT-PCR of pancreatic markers in
pancreata explanted from neonate pups. Grey columns: controls (embryos injected with vehicle). Black columns: TAT-MafA-treated embryos. Bars:
standard error. Y axis: -fold increase over control (=1). (B) Total insulin extraction of pancreata explanted from neonate embryos injected in utero with
vehicle (open column) or TAT-MafA (black column). Y axis: units of insulin (pM).
doi:10.1371/journal.pone.0022364.g004
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sites. BL21 E. coli bacteria were transformed with the plasmid,
which also contains a 6xHis tag for affinity purification. Bacteria
were cultured in LB medium with kanamycin (50 mg/ml) at 37uC
to OD600 nm=0.8. Protein expression was induced with 1 mM
IPTG (isopropyl b-D-thiogalactopyranoside) for 4 hours. After
induction, the cells were harvested by centrifugation at 5,000 g for
15 min and washed with 16PBS. The pellet was frozen at 280uC
and subsequently resuspended in urea Buffer (6 M urea, 20 mM
Hepes, 500 mM NaCL, 5 mM imidazole, pH 7.14) plus protease
inhibitor (1 mM), lysozyme and benzonase. After incubation on
ice (40 min), the pellet was sonicated (21 s pulse with 1 min
between each pulse) and then centrifuged for 25 min at 12,000 g.
Solubilized protein was purified by affinity chromatography on a
1 ml His-Trap column under denaturing conditions and elution in
non-denaturing buffer. Chromatography was performed in three
consecutive steps using a GE Healthcare A ¨kta purifier System
(Waukeska, WI). First step: starting buffer (6 M urea, 20 mM
Hepes, 500 mM NaCL, 5 mM imidazole, pH 7.14), end buffer
(6 M urea, 20 mM Hepes, 500 mM NaCL, 100 mM imidazole,
pH 7.14). Second step: starting buffer (6 M urea, 20 mM Hepes,
500 mM NaCL, 100 mM imidazole, pH 7.14), end buffer
(20 mM Hepes, 500 mM NaCL, 100 mM imidazole, pH 7.14).
Third step: starting buffer (20 mM Hepes, 500 mM NaCL,
100 mM imidazole, pH 7.14), elution buffer (20 mM Hepes,
250 mM NaCL, 750 mM imidazole, pH 7.14).
Electrophoretic mobility shift assay (EMSA)
To study the DNA-binding specificity of TAT-MafA, we used
the Pierce LightShiftH Chemiluminescent EMSA Kit (Cat. 20148).
DNA oligos were custom ordered from Sigma-Aldrich (St Louis,
MO). Hybridization of complementary DNA chains was carried
out according to the thermocycler method in Technical Tip # 45
from Thermo Scientific. To determine the proper concentration of
labeled DNA, the 1 pM stock of biotin-labeled DNA was diluted to
various concentrations, 20 ul of which were run in a Lonza PAGErH
GoldPrecastGel(Cat.58525)at100 Vuntilthedyehadmigrated2/
3 of the way down the gel. The gel was then transferred to a nylon
membrane and biotin-labeled DNA was detected by chemiluminis-
cence. A dilution of 200 fmol/ml was deemed optimal for imaging.
Unlabeled DNA was used as a competitor at a concentration of
10 pmol/ml for the entire procedure. TAT-MafA phosphorylation
Figure 5. Histological analysis of TAT-MafA-treated pancreata in neonate pups. (A) Representative section of a control pancreas (in utero
injection: vehicle), showing a disorganized pattern of b cell expression (red) in islets. (B) Representative section of a pancreas of a neonate pup
treated in utero with TAT-MafA. Islets are larger, rounder and more organized than in controls. Size bars: 500 mm. (C–D) High magnification confocal
microphotograph of control neonatal (C) and TAT-MafA-treated (D) pancreata. While the former exhibits small islets in the process of coalescence,
islets from the latter are already larger in size. Prohormone convertase (PC) 1/3 staining (green) was similar in both samples despite a trend in favor of
the experimental group by qRT-PCR (fig. 4). Glucagon staining (purple) was stronger in (D) at the same exposure. Size bars: 75 mm. (E) Glut-2 staining
(green) is not evident in control samples, but can be observed in TAT-MafA samples (F). Size bars: 75 mm.
doi:10.1371/journal.pone.0022364.g005
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Biolabs, Ipswich, MA) according to the manufacturer’s instructions.
Protein was treated with kinase or PBS (control). In addition, kinase
alone, where PBS was used instead of TAT-MafA protein, was also
included as a control. These samples were subsequently used for
preparation of the three main experimental EMSA binding reactions
(PBS treated TAT-MafA; ERK2 kinase treated TAT-MafA; ERK2
kinase alone). 82.15 mg of TAT-MafA protein were used. Incubation
with the kinase was done at 37uC for 1 h. During the incubation, the
binding reactions were prepared from the Pierce EMSA Kit along
with the three kit control reactions. Phosphorylation reaction
products were then subjected to an additional 20 minute incubation
for protein-DNA binding. 5 ml of loading buffer were added and
samples run until the dye front was L of the total length of the gel.
Following transfer to a nylon membrane, the samples were cross-
linked and analyzed by chemiluminiscence.
In vitro culture of embryonic pancreatic buds and
intrauterine embryo injection
All methods herein described involving the use of animals have
been approved by the University of Miami IACUC. C57BL/6
mice (20–25 g body weight) were used for all animal experiments.
Mating of the animals was set later in the day, and the following
day the females were checked for vaginal plugs. Noon of that day
was considered to be gestational time point e0.5. Pancreatic buds
at e14.5 were explanted and cultured as described in [34]. For
intrauterine embryo injection, pregnancy was confirmed by
ultrasound imaging (Vevo 770, VisualSonics, Toronto, ON,
Canada) at e17.5. At this time, pregnant females were anesthetized
by inhalation of 2% isofluorane and placed on a preheated
platform in the supine position with ECG electrodes taped to their
legs to monitor the heart rate. Body temperature was maintained
with the heating pad between 36uC and 38uC. Hair was removed
from the abdomen using a chemical hair remover (Nair, Carter-
Horner, Mississauga, ON, Canada). To provide a coupling
medium for the transducer, a prewarmed ultrasound gel
(Allegiance; Cardinal Health, McGaw Park, Illinois) was spread
over the abdominal wall. For TAT-b-galactosidase injection
experiments, protein (2 mg/ml) was labeled with Alexa Fluor 568
labeling kit (Invitrogen, Carlsbad, CA). Each visualized e17.5
embryo was injected intracardially with using a 500 mL syringe
(Hamilton Company, catalogue No 81242, Reno, NV). The
needle was guided using an ultrasound bio-microscope with B-
mode image (Vevo 770, VisualSonics, Toronto, ON, Canada).
Total volume of protein for each embryo was 10 ml. The mothers
were sacrificed 4 h later and the pancreata of the embryos
microdissected and examined using a multi-photon confocal
microscope (Leica) to study the distribution of labeled TAT-b-
galactosidase. For TAT-MafA experiments, seven to eight
embryos per animal were injected with TAT-MafA (2.1 ug/ml)
or protein vehicle (control). TAT alone was not used in controls
because we and others have previously established that the TAT
peptide is inert from a biological point of view [26,50]. Pancreata
were isolated for analysis immediately after birth (about e19.5–
20.5).
Quantitative Real-Time PCR
Total RNA was purified using Qiagen kits (QIAShredder,
RNeasy and DNase-free). The First-Strand system (Roche, Basel,
Switzerland) was used to generate cDNA (random oligomers).
Relative gene expression was calculated using Taqman assays in
either 7500 Fast, StepOne Plus or 7900 Real Time PCR cyclers
(Applied Biosystems, Life Technologies, Carlsbad, CA). The latter
was used to run custom-made TaqmanH Low Density Microarray
(TLDA) cards, which allow the simultaneous qRT-PCR analysis of
up to 384 samples. The DCt method for relative quantification was
deemed optimal for our application after discussion with Applied
Biosystems researchers. All assays are designed to span exon-exon
junctions, thus eliminating the possibility of genomic DNA
contamination. qRT-PCR results are the average of several
independent experiments. In addition, in each experiment each
marker was analyzed in triplicates. Gene expression was
normalized against 18S rRNA. This endogenous control has been
validated in our system and proven extremely stable and more
accurate than other standards.
Total insulin extraction
Pancreata were lysed by ultrafreezing in the presence of 180 ml
of T-PER (Thermo Scientific) and 20 ml of anti-protease (Roche),
followed by physical maceration. Insulin was quantified by the
LincoPlex endocrine panel kit (Linco-Invitrogen) using a Bioplex
platform (Bio-Rad Laboratories, Inc).
Western blots and immunofluorescence
Western blots were done according to standard methods [50].
The primary antibody for Maf-A was Abcam ab17976 (Cam-
bridge, MA), used at a 1:20,000 dilution. For immunofluores-
cence, embryonic pancreata were fixed in 4% paraformalde-
hyde overnight at 4uC and then embedded in OCT for 10 mm-
thick sectioning. Staining was done with primary antibodies
against anti-Prohormone Convertase PC1/PC3 (AB10553;
Millipore, Billerica, MA) (1:25 dilution), GLUT2 (ab85715;
Abcam, 10 mg/mL), glucacon (A0565; Dako, Glostrup, Den-
mark) (1:250 dilution) and insulin (A0564; Dako) (1:250
dilution). Secondary antibodies: Donkey anti-rabbit 488, donkey
anti-mouse 647 (both from Molecular Probes/Invitrogen,
Carlsbad, CA) and DyLight 594 donkey anti-guinea pig
(Jackson ImmunoResearch, West Grove, PA) (1:400 dilution).
Nucleus counter-staining was done with 49,6-diamidino-2-
phenylindole (DAPI) (St. Louis, MO). Images were captured
using a Leica SP5 inverted confocal microscope with motorized
stage (206dry).
Statistical analyses
Results are expressed as mean 6 standard deviation (SD).
The statistical significance of differences was assessed by the
two-tailed Student’s t test. In all comparisons, a value of P,0.05
was considered statistically significant. Sample size was deter-
mined by power analysis (5% alpha error level, 50% beta error
level).
Supporting Information
Figure S1 Gene expression analysis of TAT-MafA-
treated e17.5 pancreata. (A) qRT-PCR of pancreatic markers
in organs explanted from e17.5 embryos. Grey columns: controls
(explants treated with vehicle). Black columns: TAT-MafA-treated
explants. Bars: standard error. Y axis: -fold increase over control
(=1). None of the differences is statistically significant.
(TIF)
Figure S2 In vivo penetrability of TAT-fused proteins
after in utero intra-cardiac injection. (A–D) Alexa Fluor
568-labeled TAT-bgal is observed in the pancreas of embryos 4 h
after the injection by two-photon confocal microscopy. (D) Control
(pancreas of embryo injected with vehicle). Size bar: 75 mm.
(TIF)
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